Nurx Secures $22.5 Million to Continue Expanding Patient Growth

Nurx made its name through telehealth prescription and delivery of birth control pills but recently expanded its offerings to include other reproductive health areas.

FREMONT, CA: Nurx, the largest digital practice for women's health, raised an additional $22.5 million in Series C funding round. New investors Trustbridge, Comcast Ventures, and Wittington Ventures participated in the round along with existing investors Union Square Ventures and Kleiner Perkins Digital Growth Fund.

The company is focused on providing high-quality care for "sensitive health" needs, such as contraception, HIV prevention with PrEP, STI testing and treatment, and herpes treatment, which can be challenging to access and often carry shame and stigma. The company is also one of the few digital practices that accept health insurance while also offering affordable pricing for patients without insurance.

"Nurx has demonstrated consistent growth over the last year and as the pandemic placed strain on our healthcare system, the company was well positioned to capture the sudden surge in demand for telemedicine services," said Sam Landman, Comcast Ventures Managing Director. "The Nurx team has established a leadership position with birth control and women's health while also steadily taking market share across several additional sensitive health conditions. We're eager to see the team continue their accelerated growth, bolstered by shifting consumer expectations and offerings in new categories."

Nurx will use the latest capital to continue investing in sensitive health services, starting with personalized treatment for headaches and migraines. Nurx is well-positioned to expand access to treatment within its current patient community of over 300,000 women. Despite being one of the most prevalent health conditions and having a significant impact on everyday well-being, headaches and migraines are often misunderstood and misdiagnosed.

"As the largest and most trusted digital practice for women's health, our team was well positioned to leverage our momentum over the last year and meet the surge in demand for our services when the COVID-19 pandemic hit and uprooted our healthcare system," said Nurx CEO Varsha Rao. "I'm proud of our team's dedication to providing our patients with the best care possible so they can remain safely at home. Over the last few months we've further accelerated our patient growth across all of our services. We're excited to build on our vision of treating and managing more sensitive healthcare needs that carry stigma and largely impact women by launching our migraines and headache service."

Nurx expects to reach profitability by early 2021 and has provided over 1 million virtual consultations. The COVID-19 pandemic has also increased demand for the company's services, with a 75 percent increase in new patient requests for birth control during the first half of the year, totaling over 250,000 new patient requests. The company has also received twice as many requests for STI home testing and treatment, PrEP for HIV prevention, and oral and genital herpes treatment services in recent months.